Clinical Trial Update: Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating the efficacy and safety of SH-L-749 in indolent B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• SH-L-749

Snippet

Sponsor: Bayer | Conditions: Non-Hodgkin's Lymphoma, Lymphoma, B-Cell | Phase 2 | Status: COMPLETED